IP Library Granted Patent US 9,669,070
Granted Patent B2
US 9,669,070 · App. 14/481,959 · Granted Jun 6, 2017

Treatment and prevention of radiation injury using MFG-E8

Inventor: Ping Wang (Roslyn, NY)
Assignee: The Feinstein Institute For Medical Research
A61K38/1808
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,669,070
App. No.
14/481,959
Granted
Jun 6, 2017
Kind
B2
Abstract

Methods and compositions are disclosed for treating and preventing radiation injury using milk fat globule epidermal growth factor-factor VIII (MFG-E8).

Claims (10)

1. A method of treating radiation damage in a subject exposed to radiation therapy for treatment of a disease comprising administering to the subject a milk fat globule epidermal growth factor-factor VIII (MFG-E8) in an amount effective to reduce radiation-induced intestinal epithelial cell death in a subject following exposure to radiation therapy for treatment of a disease, wherein MFG-E8 is administered to the subject either before radiation therapy or within 24 hours after onset of radiation therapy.

2. The method of claim 1 , wherein the disease is cancer.

3. The method of claim 1 , wherein treatment of the subject with MFG-E8 reduces a decrease in body weight following exposure to radiation.

4. The method of claim 1 , wherein treatment of the subject with MFG-E8 reduces a decrease in MFG-E8 following exposure to radiation.

5. The method of claim 1 , wherein the MFG-E8 is a recombinant human MFG-E8 (rhMFG-E8).

6. The method of claim 5 , wherein the rhMFG-E8 has an amino acid sequence that is at least 95% identical to human MFG-E8 (hMFG-E8) (SEQ ID NO:1).

7. The method of claim 1 , wherein the MFG-E8 is a human MFG-E8.

8. The method of claim 7 , wherein the MFG-E8 has an amino acid sequence that is at least 95% identical to human MFG-E8 (SEQ ID NO:1).

9. The method of claim 1 , wherein the MFG-E8 is non-glycosylated.

10. The method of claim 1 , wherein the subject does not have sepsis.

Assignments (3)
CHANGE OF NAME Recorded Aug 21, 2019
From: THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
To: THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
Reel/Frame 050114/0931 →
CONFIRMATORY LICENSE Recorded Apr 24, 2015
From: FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035499/0159 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2014
From: WANG, PING
To: THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
Reel/Frame 033861/0533 →
Continuity (2)
Provisional Application 61878705 · Sep 17, 2013
Related Publication 20150080304A1 · Mar 19, 2015